- Conditions
- Migraine, Pain, Nausea, Vomiting, Aura
- Interventions
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
- Drug · Other
- Lead sponsor
- Charleston Laboratories, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 2,673
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, La Jolla, California • Gainesville, Florida
- Conditions
- Recreational Drug Use
- Interventions
- PF614, Oxycodone Hydrochloride 40 mg, Placebo
- Drug
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
- Interventions
- Cal-Mag Butyrate, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Long Beach, California • Miami, Florida • Salt Lake City, Utah
- Conditions
- Asthma
- Interventions
- BI 671800, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
- Conditions
- Post Electrophysiology Procedure Pain
- Interventions
- Acetaminophen, Placebo Oral Tablet
- Drug
- Lead sponsor
- Ascension Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Grand Blanc, Michigan
- Conditions
- Autosomal Dominant Polycystic Kidney, ADPKD
- Interventions
- Lixivaptan, Placebo
- Drug
- Lead sponsor
- Palladio Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
- Conditions
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- GKT137831, Placebo
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more
- Conditions
- Insulin Resistance, Mild Cognitive Impairment, Cognitive Decline, Neurodegenerative Disorders
- Interventions
- Sabroxy®, Placebo
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, COLAL-PRED
- Drug
- Lead sponsor
- Prometheus Laboratories
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
- Conditions
- Bipolar II Disorder
- Interventions
- Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 19 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Hearing Loss, Head and Neck Cancer
- Interventions
- Placebo, Atorvastatin
- Other · Drug
- Lead sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
- Conditions
- Celiac Disease
- Interventions
- larazotide acetate, Placebo
- Drug
- Lead sponsor
- 9 Meters Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Boston, Massachusetts + 6 more
- Conditions
- Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
- Interventions
- Pexidartinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Sleep Disturbance, Heart Failure
- Interventions
- Zolpidem Tartrate, Placebo oral capsule
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Crohn's Disease
- Interventions
- GSK1605786A, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 48
- States / cities
- Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 43 more
- Conditions
- Social Anxiety Disorder
- Interventions
- Fear extinction, Cannabidiol Cap/Tab, Placebo
- Behavioral · Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Nicotine Dependence
- Interventions
- Intravenous Nicotine, Progesterone
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Clostridium Difficile Infection
- Interventions
- Cadazolid, Vancomycin, Placebo-matching cadazolid, Placebo-matching vancomycin
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Newark, Delaware • Jacksonville, Florida • Orlando, Florida + 8 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Aggressive Behavior in Fragile X Syndome
- Interventions
- SRX246, Placebo
- Drug
- Lead sponsor
- Azevan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
- Conditions
- Bone Diseases, Metabolic, Osteoporosis, Postmenopausal
- Interventions
- potassium citrate
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York